Sociodemographic and clinical characteristics of patients with MI on 28 June to 11 August 2020 at NICVD, Dhaka, Bangladesh
| Characteristics | Patients with MI (n=280) | SARS-CoV-2 infected (n=36) | No infection n=244 | P value |
| Age in years, mean (±SD) | 54.5 (11.8) | 54.5 (13.2) | 54.5 (11.6) | 0.954 |
| <40 | 26 (9.3) | 3 (8.3) | 23 (9.4) | Ref. |
| 40–64 | 193 (68.9) | 24 (66.7) | 169 (69.3) | 0.899 |
| ≥65 | 61 (21.8) | 9 (25.0) | 52 (21.3) | 0.683 |
| Male, n (%) | 220 (78.6) | 30 (83.3) | 190 (77.9) | 0.456 |
| Location of residence, n (%) | ||||
| Suburban | 136 (48.6) | 1 (2.8) | 41 (16.8) | Ref. |
| Urban | 102 (36.4) | 13 (36.1) | 89 (36.5) | 0.091 |
| Rural | 42 (15.0) | 22 (61.1) | 114 (46.7) | 0.020* |
| Education, years of school attendance, n (%) | ||||
| None | 67 (23.9) | 8 (22.2) | 59 (24.2) | Ref. |
| 1–5 | 132 (47.1) | 16 (44.4) | 116 (47.5) | 0.971 |
| 6–10 | 29 (10.4) | 2 (5.6) | 27 (11.1) | 0.500 |
| 11–12 | 27 (9.6) | 6 (16.7) | 21 (8.6) | 0.180 |
| ≥13 | 25 (8.9) | 21 (8.6) | 21 (8.6) | 0.606 |
| Travel history to COVID-19 hotspot n (%) | 49 (17.6) | 3 (8.3) | 46 (18.9) | 0.119 |
| Medical history | ||||
| Body mass index†, mean (±SD)1 | 23.4 (3.6) | 23.9 (3.6) | 23.3 (3.6) | 0.389 |
| Overweight (BMI† >25) | 84 (30.0) | 11 (30.6) | 73 (29.9) | 0.938 |
| Diabetes mellitus, n (%) | 107 (38.2) | 9 (25.0) | 98 (40.2) | 0.099 |
| Smoking status, n (%) | ||||
| Never smoked | 112 (40.0) | 17 (47.2) | 95 (38.9) | Ref. |
| Former smoker | 53 (18.9) | 10 (27.8) | 43 (17.6) | 0.508 |
| Current smoker | 115 (41.1) | 9 (25.0) | 106 (43.4) | 0.098 |
| Hyperlipidaemia, n (%) | 47 (16.8) | 6 (16.7) | 41 (16.8) | 0.984 |
| Hypertension, n (%) | 136 (48.6) | 19 (52.8) | 117 (48.0) | 0.589 |
| Previous myocardial infarction, n (%) | 35 (12.5) | 4 (11.1) | 31 (12.7) | 0.787 |
| Previous PCI, n (%) | 13 (4.6) | 1 (2.8) | 12 (4.9) | 0.569 |
| Previous coronary artery bypass graft, n (%) | 5 (1.8) | 1 (2.8) | 4 (1.6) | 0.630 |
| STEMI, n (%) | 140 (50.0) | 18 (50.0) | 122 (50.0) | – |
| NSTEMI, n (%) | 140 (50.0) | 18 (50.0) | 122 (50.0) | – |
| Hospital admission in the past 14 days, n (%) | 15 | 3 (8.3) | 12 (4.9) | 0.396 |
| Discharge medications, n (%) | ||||
| ASA | 256 (97.0) | 33 (94.3) | 223 (97.4) | 0.320 |
| P2Y12 inhibitor | 255 (96.2) | 34 (97.1) | 221 (96.1) | 0.909 |
| β-blocker | 177 (66.8) | 22 (62.9) | 155 (67.4) | 0.596 |
| ACEI/ARB | 176 (66.4) | 24 (68.6) | 152 (66.1) | 0.772 |
| Statin | 262 (98.9) | 34 (97.1) | 228 (99.1) | 0.300 |
| Nitrate | 207 (78.1) | 29 (82.9) | 178 (77.4) | 0.466 |
| Diuretic | 60 (22.6) | 8 (22.9) | 52 (22.6) | 0.974 |
| Azithromycin | 12 (4.5) | 1 (2.9) | 11 (4.8) | 0.610 |
*Significant at p≤0.05.
†Body mass index=kg/m2.
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; ASA, acetylsalicylic acid; MI, myocardial infarction; NICVD, National Institute of Cardiovascular Diseases; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation; STEMI, ST-segment elevation myocardial infarction.